Turning up the Heat with Therapeutic Epigenome Editing.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29304336.
- Also identified by DOI 10.1016/j.stem.2017.12.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CRISPR-Cas9 has been touted for therapeutic genome editing, but limitations include inefficient correction of disease-causing mutations and off-target mutagenesis. In the latest issue of Cell, Liao et al. (2017) show that a modified version of CRISPR-Cas9 can target and activate key therapeutic genes in vivo without altering DNA sequence identity.
Medical subject headings
- CRISPR-Cas Systems
- Mutagenesis